olmesartan + empagliflozin

olmesartan + empagliflozin is a combination of two pharmaceutical agents: olmesartan, an angiotensin II receptor blocker (ARB), and empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Olmesartan works by blocking the vasoconstrictor effects of angiotensin II, leading to vasodilation and reduced blood pressure. Empagliflozin inhibits SGLT2 in the proximal renal tubules, increasing urinary glucose excretion and lowering blood glucose levels. This combination is used for the management of hypertension and type 2 diabetes mellitus, offering synergistic effects for blood pressure and glycemic control. The combination is indicated for patients who require both antihypertensive and antidiabetic therapy.